Spin-off
Sealing leaks in the stomach or intestine
TechTransfer
ETH Zurich
ETH Pioneer Fellow Alexandre Anthis has developed a patch that seals surgical sutures on the intestines or the stomach. The material designed can also detect any leakage at an early stage – thus preventing serious complications.
Plant-based prawns to protect the marine environment
TechTransfer
ETH Zurich
The growth in demand for fish and seafood is harming stocks and valuable ecosystems. In response, food technologist Lukas Böcker and food chemist Severin Eder are developing microalgae-based seafood substitutes in their joint Pioneer Fellowship project.
Start-up brings RNA sequencing into the age of big data
Research
EPFL
EPFL spin-off Alithea Genomics has developed a system that allows scientists to easily tag bulk RNA samples with molecular barcodes so they can be processed by the hundreds in one single tube. The technology promises to dramatically shorten and streamline sample preparation for RNA sequencing, which will enable new applications for this technology, such as biomarker discovery and drug development.
Eight ETH start-ups win Venture award
TechTransfer
ETH Zurich
The Venture Awards for Swiss start-ups were presented yesterday evening for the 25th time. In addition to the three certified ETH spin-offs DeepJudge, Kaspar& and Versics, the 15 winners included five other start-ups founded by ETH students and alumni.
Wearable muscles
Research
ETH Zurich
Researchers at ETH Zurich have developed a wearable textile exomuscle that serves as an extra layer of muscles. They aim to use it to increase the upper body strength and endurance of people with restricted mobility.
Turning drug discovery into speed dating
TechTransfer
EPFL
EPFL spin-off ArcoScreen has developed a platform that turns the discovery of new drugs for Alzheimer’s and Parkinson’s disease, diabetes and cancer from a marathon into a sprint. The firm’s microfluidic readout system assesses the response of G-protein-coupled receptors (GPCRs) to new substances, delivering significant time and financial gains for pharmaceutical companies.
Page 8 of 12